GSK Has Big Ambitions In Vaccines, With An Eye On Blockbuster Opportunities
The company is focusing on new technologies, including mRNA, and expects the vaccines business to deliver a high single-digit sales CAGR over the next five years.
You may also be interested in...
The company has not revealed any details of the potential safety issue that led to the decision.
The second quarter could mark a financial turning point for big pharma as demand rebounds from the pandemic, but variability remains across portfolios and therapeutic areas.
Phase III trials found vaccine effectiveness was 68.2% in recipients with autologous hematopoietic stem cell transplant and 87.2% in those with hematologic malignancies, GSK tells Advisory Committee on Immunization Practices.